Business Wire

NIELSENIQ

9.2.2021 10:02:07 CET | Business Wire | Press release

Share
NielsenIQ Connect Partner Network Expands Globally into Asia and Europe, Strengthening the Largest Open Ecosystem of Tech-driven Partners For Streamlining Data For The CPG Industry

The NielsenIQ Connect Partner Network (CPN) has expanded its business globally into Asia and Europe, broadening the reach and influence of the network while also providing partners access to global data sets.

As the Consumer Packaged Goods (CPG) industry’s largest open ecosystem of tech-driven solution providers, the NielsenIQ Connect Partner Network has continued on its growth trajectory by selectively adding innovative partners since its launch in 2016. Now, by entering new markets, the network will expand its value to both clients and partners across the globe.

“The NielsenIQ Connect Partner Network is not only core to the success and growth of Nielsen, but also to the CPG industry as a whole”, said Johan Sjostrand, Global President Retail Intelligence, NielsenIQ. “In addition to the network expanding into global markets, it is also continuously growing by way of the number of member companies, as we recently surpassed 100 partners. We are able to continuously attract powerful partners because we never stop evolving our ways of working with them, and the opportunities and benefits provided to them. The network is a win for our clients, our partners, and NielsenIQ overall, which makes the network so unique and leads us to believe its influence will only expand from here.”

Partners are provided with streamlined access to industry-leading data, enabling them to enhance their own solutions. The diversity of markets that Asia and Europe encompass will provide unique opportunities and benefits to the CPG industry as a whole.

In a recent survey conducted by the NielsenIQ Connect Partner Network team, 83% of partners responded that the network has helped them create a stronger, better offering for their clients, while over 90% of partners said they were able to identify new opportunities due to their membership. NielsenIQ clients also benefit a great deal, as they can work directly with any of our partners who specialize across a broad range of areas including demand planning, data harmonization, machine learning, and AI-driven promotion, to name a few. With the NielsenIQ Connect Partner Network, clients and partners work with a common dataset, enabling them to easily bridge insights and save time typically spent figuring out who to work with, how to get data to who they decide to work with, and how to make sense of disparate data sources.

“We are extremely excited about the global expansion of NielsenIQ’s Connect Partner Network and what this means for us and our clients'', said Satish Raman, Chief Strategy Officer, Fractal Analytics. “One of the things we love most about the network is its openness, enabling us to freely and easily collaborate with NielsenIQ, our clients and other Connected Partners in the network. The opportunity to scale that collaboration globally will open more avenues to enter new markets, expand our client base, increase the depth and breadth of our engagements, and drive our solution and product enhancements. This is a profound step forward for the network and big news for NielsenIQ, but I also see this as big news for Fractal and all other partners, because any enhancement to the network will ultimately add value to us and our clients.”

“We are very proud of the success, expansion, and continued growth of the Network”, said Brett Jones, SVP, Global Leader, NielsenIQ Connect Partner Network. “Making this network truly global is a major milestone for us. It has always been our goal to evolve in a variety of ways, whether that be through the addition of new partners, the enhancement of our offerings, or entering new markets like we are now with Asia and Europe. There are even bigger things ahead for the Connected Partner Network as we never stop exploring avenues to positively impact the CPG landscape.”

For additional information, or if you are interested in becoming a NielsenIQ Connect Partner Network member, please go to https://www.nielsen.com/us/en/solutions/capabilities/connected-partner-program/ . For a list of all partners please go to https://microsites.nielsen.com/connectedpartnernetwork/

ABOUT NIELSEN

Nielsen Holdings plc (NYSE: NLSN) is a global measurement and data analytics company that provides the most complete and trusted view available of consumers and markets worldwide. Nielsen is divided into two business units. Nielsen Global Media provides media and advertising industries with unbiased and reliable metrics that create a shared understanding of the industry required for markets to function. NielsenIQ (formerly known as Nielsen Global Connect) provides consumer packaged goods manufacturers and retailers with accurate, actionable information and insights and a complete picture of the complex and changing marketplace that companies need to innovate and grow.

Our approach marries proprietary Nielsen data with other data sources to help clients around the world understand what’s happening now, what’s happening next, and how to best act on this knowledge.

An S&P 500 company, Nielsen has operations in nearly 100 countries, covering more than 90% of the world’s population. For more information, visit www.nielsen.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye